Sensitivity | Specificity | Period Prevalence | Positive Post-Test Probability | Negative Post-Test Probability | Positive Likelihood Ratio | Negative Likelihood Ratio | False Positive rate | False Negative Rate | Study Developed Tool Negative Post-Test Probability at Citation Bacteremia Period Prevalence | |
---|---|---|---|---|---|---|---|---|---|---|
Study Developed Tool | ||||||||||
P value > 0.415 | 0.90 | 0.80 | 0.51 | 0.82 | 0.11 | 4.50 | 0.12 | 0.20 | 0.10 | – |
Mahieu et al., 2000 [7] | ||||||||||
Score ≥ 8 | 0.95 | 0.43 | 0.41 | 0.54 | 0.08 | 1.67 | 0.12 | 0.57 | 0.05 | 0.08 |
Score ≥ 11 | 0.60 | 0.84 | 0.41 | 0.72 | 0.25 | 3.75 | 0.48 | 0.16 | 0.40 | 0.08 |
Score ≥ 14 | 0.26 | 1.00 | 0.41 | 1.00 | 0.34 | 9999.00 | 0.74 | 0.00 | 0.74 | 0.08 |
Score ≥ 11 plus positive culture | 0.72 | 0.87 | 0.41 | 0.79 | 0.18 | 5.50 | 0.32 | 0.13 | 0.28 | 0.08 |
Mahieu et al., 2002 [5] | ||||||||||
Score ≥ 11 | 0.84 | 0.42 | 0.55 | 0.64 | 0.32 | 1.45 | 0.38 | 0.58 | 0.16 | 0.13 |
Score ≥ 11 + 3 RFs | 0.82 | 0.67 | 0.55 | 0.75 | 0.25 | 2.48 | 0.27 | 0.33 | 0.18 | 0.13 |
Singh et al., 2003 [8] | ||||||||||
Score ≥ 1 | 0.87 | 0.29 | 0.29 | 0.33 | 0.16 | 1.23 | 0.45 | 0.71 | 0.13 | 0.05 |
Score ≥ 2 | 0.53 | 0.80 | 0.29 | 0.52 | 0.19 | 2.65 | 0.59 | 0.20 | 0.47 | 0.05 |
Okascharoen et al., 2005 [9] | ||||||||||
Score ≥ 4 | 0.82 | 0.74 | 0.17 | 0.39 | 0.05 | 3.15 | 0.24 | 0.26 | 0.18 | 0.02 |
Score ≥ 5 | 0.70 | 0.82 | 0.17 | 0.44 | 0.07 | 3.89 | 0.37 | 0.18 | 0.30 | 0.02 |
Score ≥ 6 | 0.47 | 0.96 | 0.17 | 0.71 | 0.10 | 12.00 | 0.55 | 0.04 | 0.53 | 0.02 |
Dalgic et al., 2006 [10] | ||||||||||
Score = 6–12 | 0.56 | 0.71 | 0.39 | 0.55 | 0.28 | 1.93 | 0.62 | 0.29 | 0.44 | 0.07 |
Okascharoen et al., 2007 [6] | ||||||||||
Validation Cohort Score ≤ 3 (low risk of sepsis) | 0.97 | 0.39 | 0.33 | 0.43 | 0.40 | 1.6 | 0.07 | 0.61 | 0.03 | 0.06 |
Validation Cohort Score 4–7 (medium risk of sepsis) | 0.77 | 0.43 | 0.33 | 0.48 | 0.27 | 1.35 | 0.53 | 0.57 | 0.23 | 0.06 |
Validation Cohort Score ≥ 8 (high risk of sepsis) | 0.2 | 0.98 | 0.33 | 0.99 | 0.85 | 10 | 0.82 | 0.02 | 0.8 | 0.06 |
Kudawla et al., 2008 [11] | ||||||||||
≥1 clinical signs | 0.90 | 0.23 | 0.27 | 0.30 | 0.14 | 1.17 | 0.43 | 0.77 | 0.10 | 0.04 |
≥2 clinical signs | 0.52 | 0.65 | 0.27 | 0.36 | 0.21 | 1.49 | 0.74 | 0.35 | 0.48 | 0.04 |
≥2 markers | 0.48 | 0.70 | 0.27 | 0.37 | 0.21 | 1.60 | 0.74 | 0.30 | 0.52 | 0.04 |
≥1 clinical sign + ≥ 2 markers | 0.95 | 0.18 | 0.27 | 0.30 | 0.09 | 1.16 | 0.28 | 0.82 | 0.05 | 0.04 |
Rosenberg et al., 2010 [12] | ||||||||||
Score ≥ 1 | 0.77 | 0.50 | 0.54 | 0.64 | 0.35 | 1.54 | 0.46 | 0.50 | 0.23 | 0.12 |
Score ≥ 2 | 0.42 | 0.82 | 0.54 | 0.73 | 0.45 | 2.33 | 0.71 | 0.18 | 0.58 | 0.12 |
Bekhof et al., 2013 [13] | ||||||||||
1 of 4 signs present | 0.97 | 0.37 | 0.27 | 0.36 | 0.03 | 1.54 | 0.08 | 0.63 | 0.03 | 0.04 |